Effects of interleukin-1 on cardiac fibroblast function: Relevance to post-myocardial infarction remodelling

Vascular Pharmacology

Volumn 60, Issue 1, 2014, Pages 1-7

  Turner, Neil A ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

Cardiac fibroblast; Interleukin 1; Myocardial infarction; Signal transduction pathways; Therapies

Indexed keywords

GELATINASE A; GELATINASE B; INTERLEUKIN 1; INTERLEUKIN 33; INTERLEUKIN 6; INTERSTITIAL COLLAGENASE; MATRIX METALLOPROTEINASE 16; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN LIKE RECEPTOR; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

CARDIAC FIBROBLAST; CARDIOMYOPATHY; CELL DIFFERENTIATION; CELL FUNCTION; CELL MATURATION; CELL MIGRATION; CELL PROLIFERATION; DOWN REGULATION; FIBROBLAST; GRANULATION TISSUE; HEART INFARCTION; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HUMAN; INNATE IMMUNITY; MACROPHAGE; MAST CELL; MYOCARDITIS; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

CARDIAC FIBROBLAST; INTERLEUKIN-1; MYOCARDIAL INFARCTION; SIGNAL TRANSDUCTION PATHWAYS; THERAPIES;

ANIMALS; CELL PROLIFERATION; EXTRACELLULAR MATRIX; FIBROBLASTS; HUMANS; INTERLEUKIN-1; MYOCARDIAL INFARCTION; RECEPTORS, INTERLEUKIN-1 TYPE I; SIGNAL TRANSDUCTION; VENTRICULAR REMODELING;

EID: 84892506135     PISSN: 15371891     EISSN: 18793649     Source Type: Journal    
DOI: 10.1016/j.vph.2013.06.002     Document Type: Review

References (85)

1. Abbate A., Kontos M.C., Grizzard J.D., Biondi-Zoccai G.G., Van Tassell B.W., Robati R., et al. Interleukin-1 blockade with Anakinra to prevent adverse cardiac remodeling after acute myocardial infarction (Virginia Commonwealth University Anakinra Remodeling Trial [VCU-ART] Pilot study). Am J Cardiol 2010, 105:1371-1377.
2. Abbate A., Van Tassell B.W., Biondi-Zoccai G., Kontos M.C., Grizzard J.D., Spillman D.W., et al. Effects of interleukin-1 blockade with Anakinra on adverse cardiac remodeling and heart failure after acute myocardial infarction [from the Virginia Commonwealth University-Anakinra Remodeling Trial 2 (VCU-ART2) Pilot Study]. Am J Cardiol 2013, 111:1394-1400.
3. Abbate A., Van Tassell B.W., Biondi-Zoccai G.G. Blocking interleukin-1 as a novel therapeutic strategy for secondary prevention of cardiovascular events. BioDrugs 2012, 26:217-233.
4. Abbate A., Van Tassell B.W., Seropian I.M., Toldo S., Robati R., Varma A., et al. Interleukin-1beta modulation using a genetically engineered antibody prevents adverse cardiac remodelling following acute myocardial infarction in the mouse. Eur J Heart Fail 2010, 12:319-322.
5. Adachi O., Kawai T., Takeda K., Matsumoto M., Tsutsui H., Sakagami M., et al. Targeted disruption of the MyD88 gene results in loss of IL-1- and IL-18-mediated function. Immunity 1998, 9:143-150.
6. Arend W.P., Palmer G., Gabay C. IL-1, IL-18, and IL-33 families of cytokines. Immunol Rev 2008, 223:20-38.
7. Arslan F., de Kleijn D.P., Pasterkamp G. Innate immune signaling in cardiac ischemia. Nat Rev Cardiol 2011, 8:292-300.
8. Banerjee I., Fuseler J.W., Price R.L., Borg T.K., Baudino T.A. Determination of cell types and numbers during cardiac development in the neonatal and adult rat and mouse. Am J Physiol Heart Circ Physiol 2007, 293:H1883-H1891.
9. Blyszczuk P., Kania G., Dieterle T., Marty R.R., Valaperti A., Berthonneche C., et al. Myeloid differentiation factor-88/interleukin-1 signaling controls cardiac fibrosis and heart failure progression in inflammatory dilated cardiomyopathy. Circ Res 2009, 105:912-920.
10. Brikos C., Wait R., Begum S., O'Neill L.A., Saklatvala J. Mass spectrometric analysis of the endogenous type I interleukin-1 (IL-1) receptor signaling complex formed after IL-1 binding identifies IL-1RAcP, MyD88, and IRAK-4 as the stable components. Mol Cell Proteomics 2007, 6:1551-1559.
11. Brown R.D., Ambler S.K., Mitchell M.D., Long C.S. The cardiac fibroblast: therapeutic target in myocardial remodeling and failure. Annu Rev Pharmacol Toxicol 2005, 45:657-687.
12. Brown R.D., Jones G.M., Laird R.E., Hudson P., Long C.S. Cytokines regulate matrix metalloproteinases and migration in cardiac fibroblasts. Biochem Biophys Res Commun 2007, 362:200-205.
13. Bujak M., Dobaczewski M., Chatila K., Mendoza L.H., Li N., Reddy A., et al. Interleukin-1 receptor type I signaling critically regulates infarct healing and cardiac remodeling. Am J Pathol 2008, 173:57-67.
14. Bujak M., Frangogiannis N.G. The role of IL-1 in the pathogenesis of heart disease. Arch Immunol Ther Exp (Warsz) 2009, 57:165-176.
15. Burstein B., Libby E., Calderone A., Nattel S. Differential behaviors of atrial versus ventricular fibroblasts: a potential role for platelet-derived growth factor in atrial-ventricular remodeling differences. Circulation 2008, 117:1630-1641.
16. Camelliti P., Green C.R., Kohl P. Structural and functional coupling of cardiac myocytes and fibroblasts. Adv Cardiol 2006, 42:132-149.
17. Chen C.J., Kono H., Golenbock D., Reed G., Akira S., Rock K.L. Identification of a key pathway required for the sterile inflammatory response triggered by dying cells. Nat Med 2007, 13:851-856.
18. Chen W., Frangogiannis N.G. Fibroblasts in post-infarction inflammation and cardiac repair. Biochim Biophys Acta 2013, 1833(4):945-953.
19. Chen W., Saxena A., Li N., Sun J., Gupta A., Lee D.W., et al. Endogenous IRAK-M attenuates postinfarction remodeling through effects on macrophages and fibroblasts. Arterioscler Thromb Vasc Biol 2012, 32:2598-2608.
20. Crossman D.C., Morton A.C., Gunn J.P., Greenwood J.P., Hall A.S., Fox K.A., et al. Investigation of the effect of interleukin-1 receptor antagonist (IL-1ra) on markers of inflammation in non-ST elevation acute coronary syndromes (The MRC-ILA-HEART Study). Trials 2008, 9:8.
21. Davis C.N., Mann E., Behrens M.M., Gaidarova S., Rebek M., Rebek J., et al. MyD88-dependent and -independent signaling by IL-1 in neurons probed by bifunctional Toll/IL-1 receptor domain/BB-loop mimetics. Proc Natl Acad Sci U S A 2006, 103:2953-2958.
22. Demyanets S., Kaun C., Pentz R., Krychtiuk K.A., Rauscher S., Pfaffenberger S., et al. Components of the interleukin-33/ST2 system are differentially expressed and regulated in human cardiac cells and in cells of the cardiac vasculature. J Mol Cell Cardiol 2013, 60:16-26.
23. Deten A., Volz H.C., Briest W., Zimmer H.G. Cardiac cytokine expression is upregulated in the acute phase after myocardial infarction. Experimental studies in rats. Cardiovasc Res 2002, 55:329-340.
24. Dewald O., Ren G., Duerr G.D., Zoerlein M., Klemm C., Gersch C., et al. Of mice and dogs: species-specific differences in the inflammatory response following myocardial infarction. Am J Pathol 2004, 164:665-677.
25. Dinarello C.A. The many worlds of reducing interleukin-1. Arthritis Rheum 2005, 52:1960-1967.
26. Dinarello C.A. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood 2011, 117:3720-3732.
27. Dinarello C.A., Simon A., van der Meer J.W. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat Rev Drug Discov 2012, 11:633-652.
28. Fernandez-Velasco M., Prieto P., Terron V., Benito G., Flores J.M., Delgado C., et al. NOD1 activation induces cardiac dysfunction and modulates cardiac fibrosis and cardiomyocyte apoptosis. PLoS One 2012, 7:e45260.
29. Flannery S., Bowie A.G. The interleukin-1 receptor-associated kinases: critical regulators of innate immune signalling. Biochem Pharmacol 2010, 80:1981-1991.
30. Frangogiannis N.G. The immune system and cardiac repair. Pharmacol Res 2008, 58:88-111.
31. Gordon J.W., Shaw J.A., Kirshenbaum L.A. Multiple facets of NF-κB in the heart: to be or not to NF-κB. Circ Res 2011, 108:1122-1132.
32. Guillen I., Blanes M., Gomez-Lechon M.J., Castell J.V. Cytokine signaling during myocardial infarction: sequential appearance of IL-1 beta and IL-6. Am J Physiol 1995, 269:R229-R235.
33. Guo X.G., Uzui H., Mizuguchi T., Ueda T., Chen J.Z., Lee J.D. Imidaprilat inhibits matrix metalloproteinase-2 activity in human cardiac fibroblasts induced by interleukin-1β via NO-dependent pathway. Int J Cardiol 2008, 126:414-420.
34. Hausenloy D.J., Tsang A., Yellon D.M. The reperfusion injury salvage kinase pathway: a common target for both ischemic preconditioning and postconditioning. Trends Cardiovasc Med 2005, 15:69-75.
35. He Y.H., Zhang H.N., Zhang G.P., Hou N., Xiao Q., Huang Y., et al. A physiological concentration of glucocorticoid inhibits the pro-inflammatory cytokine-induced proliferation of adult rat cardiac fibroblasts: roles of extracellular signal-regulated kinase 1/2 and nuclear factor-kappaB. Clin Exp Pharmacol Physiol 2011, 38:739-746.
36. Isoda K., Kamezawa Y., Tada N., Sato M., Ohsuzu F. Myocardial hypertrophy in transgenic mice overexpressing human interleukin 1α. J Card Fail 2001, 7:355-364.
37. Jugdutt B.I. Ventricular remodeling after infarction and the extracellular collagen matrix: when is enough enough?. Circulation 2003, 108:1395-1403.
38. Kawaguchi M., Takahashi M., Hata T., Kashima Y., Usui F., Morimoto H., et al. Inflammasome activation of cardiac fibroblasts is essential for myocardial ischemia/reperfusion injury. Circulation 2011, 123:594-604.
39. Ko N.Y., Mun S.H., Lee S.H., Kim J.W., Kim d.K., Kim H.S., et al. Interleukin-32α production is regulated by MyD88-dependent and independent pathways in IL-1β-stimulated human alveolar epithelial cells. Immunobiology 2011, 216:32-40.
40. Koudssi F., Lopez J.E., Villegas S., Long C.S. Cardiac fibroblasts arrest at the G1/S restriction point in response to interleukin (IL)-1β. Evidence for IL-1β-induced hypophosphorylation of the retinoblastoma protein. J Biol Chem 1998, 273:25796-25803.
41. Krenning G., Zeisberg E.M., Kalluri R. The origin of fibroblasts and mechanism of cardiac fibrosis. J Cell Physiol 2010, 225:631-637.
42. LaFramboise W.A., Scalise D., Stoodley P., Graner S.R., Guthrie R.D., Magovern J.A., et al. Cardiac fibroblasts influence cardiomyocyte phenotype in vitro. Am J Physiol Cell Physiol 2007, 292:C1799-C1808.
43. Lamkanfi M. Emerging inflammasome effector mechanisms. Nat Rev Immunol 2011, 11:213-220.
44. Lemke L.E., Bloem L.J., Fouts R., Esterman M., Sandusky G., Vlahos C.J. Decreased p38 MAPK activity in end-stage failing human myocardium: p38 MAPK α is the predominant isoform expressed in human heart. J Mol Cell Cardiol 2001, 33:1527-1540.
45. Long C.S. The role of interleukin-1 in the failing heart. Heart Fail Rev 2001, 6:81-94.
46. Maqbool A., Hemmings K.E., O'Regan D.J., Ball S.G., Porter K.E., Turner N.A. Interleukin-1 has opposing effects on connective tissue growth factor and tenascin-C expression in human cardiac fibroblasts. Matrix Biol 2013, 32:208-214.
47. Marber M.S., Rose B., Wang Y. The p38 mitogen-activated protein kinase pathway-A potential target for intervention in infarction, hypertrophy, and heart failure. J Mol Cell Cardiol 2011, 51:485-490.
48. Mezzaroma E., Toldo S., Farkas D., Seropian I.M., Van Tassell B.W., Salloum F.N., et al. The inflammasome promotes adverse cardiac remodeling following acute myocardial infarction in the mouse. Proc Natl Acad Sci U S A 2011, 108:19725-19730.
49. Mitchell M.D., Laird R.E., Brown R.D., Long C.S. IL-1β stimulates rat cardiac fibroblast migration via MAP kinase pathways. Am J Physiol Heart Circ Physiol 2007, 292:H1139-H1147.
50. Morton A.C., Foley C., Rothman A., Gunn J., Greenwood J.P., Hall A., et al. Investigation of IL-1 inhibition in patients presenting with non-ST elevation myocardial infarction acute coronary syndromes (the MRC ILA Heart Study). Heart 2011, 97:A13. [abstract]. 10.1136/heartjnl-2011-300198.15.
51. Mughal R.S., Warburton P., O'Regan D.J., Ball S.G., Turner N.A., Porter K.E. Peroxisome proliferator-activated receptor γ-independent effects of thiazolidinediones on human cardiac myofibroblast function. Clin Exp Pharmacol Physiol 2009, 36:478-486.
52. Nishikawa K., Yoshida M., Kusuhara M., Ishigami N., Isoda K., Miyazaki K., et al. Left ventricular hypertrophy in mice with a cardiac-specific overexpression of interleukin-1. Am J Physiol Heart Circ Physiol 2006, 291:H176-H183.
53. O'Neill L.A. When signaling pathways collide: positive and negative regulation of toll-like receptor signal transduction. Immunity 2008, 29:12-20.
54. Palmer J.N., Hartogensis W.E., Patten M., Fortuin F.D., Long C.S. Interleukin-1β induces cardiac myocyte growth but inhibits cardiac fibroblast proliferation in culture. J Clin Invest 1995, 95:2555-2564.
55. Peterson D.J., Ju H., Hao J., Panagia M., Chapman D.C., Dixon I.M. Expression of Gi-2 alpha and Gs alpha in myofibroblasts localized to the infarct scar in heart failure due to myocardial infarction. Cardiovasc Res 1999, 41:575-585.
56. Piacentini L., Gray M., Honbo N.Y., Chentoufi J., Bergman M., Karliner J.S. Endothelin-1 stimulates cardiac fibroblast proliferation through activation of protein kinase C. J Mol Cell Cardiol 2000, 32:565-576.
57. Porter K.E., Turner N.A. Cardiac fibroblasts: at the heart of myocardial remodeling. Pharmacol Ther 2009, 123:255-278.
58. Sinfield J.K., Das A., O'Regan D.J., Ball S.G., Porter K.E., Turner N.A. p38 MAPK alpha mediates cytokine-induced IL-6 and MMP-3 expression in human cardiac fibroblasts. Biochem Biophys Res Commun 2013, 430:419-424.
59. Siwik D.A., Chang D.L., Colucci W.S. Interleukin-1β and tumor necrosis factor-α decrease collagen synthesis and increase matrix metalloproteinase activity in cardiac fibroblasts in vitro. Circ Res 2000, 86:1259-1265.
60. Strand M.E., Herum K.M., Rana Z.A., Skrbic B., Askevold E.T., Dahl C.P., et al. Innate immune signaling induces expression and shedding of the heparan sulfate proteoglycan syndecan-4 in cardiac fibroblasts and myocytes, affecting inflammation in the pressure-overloaded heart. FEBS J 2013, 280:2228-2247.
61. Szardien S., Nef H.M., Voss S., Troidl C., Liebetrau C., Hoffmann J., et al. Regression of cardiac hypertrophy by granulocyte colony-stimulating factor-stimulated interleukin-1β synthesis. Eur Heart J 2012, 33:595-605.
62. Timmers L., Sluijter J.P., van Keulen J.K., Hoefer I.E., Nederhoff M.G., Goumans M.J., et al. Toll-like receptor 4 mediates maladaptive left ventricular remodeling and impairs cardiac function after myocardial infarction. Circ Res 2008, 102:257-264.
63. Tomasek J.J., Gabbiani G., Hinz B., Chaponnier C., Brown R.A. Myofibroblasts and mechano-regulation of connective tissue remodelling. Nat Rev Mol Cell Biol 2002, 3:349-363.
64. Turner N.A. Therapeutic regulation of cardiac fibroblast function: targeting stress-activated protein kinase pathways. Future Cardiol 2011, 7:673-691.
65. Turner N.A., Das A., O'Regan D.J., Ball S.G., Porter K.E. Human cardiac fibroblasts express ICAM-1, E-selectin and CXC chemokines in response to proinflammatory cytokine stimulation. Int J Biochem Cell Biol 2011, 43:1450-1458.
66. Turner N.A., Das A., Warburton P., O'Regan D.J., Ball S.G., Porter K.E. Interleukin-1α stimulates pro-inflammatory cytokine expression in human cardiac myofibroblasts. Am J Physiol Heart Circ Physiol 2009, 297:H1117-H1127.
67. Turner N.A., Mughal R.S., Warburton P., O'Regan D.J., Ball S.G., Porter K.E. Mechanism of TNFα-induced IL-1α, IL-1β and IL-6 expression in human cardiac fibroblasts: effects of statins and thiazolidinediones. Cardiovasc Res 2007, 76:81-90.
68. Turner N.A., Porter K.E. Regulation of myocardial matrix metalloproteinase expression and activity by cardiac fibroblasts. IUBMB Life 2012, 64:143-150.
69. Turner N.A., Porter K.E. Function and fate of myofibroblasts after myocardial infarction. Fibrogenesis Tissue Repair 2013, 6:5.
70. Turner N.A., Warburton P., O'Regan D.J., Ball S.G., Porter K.E. Modulatory effect of interleukin-1α on expression of structural matrix proteins, MMPs and TIMPs in human cardiac myofibroblasts: role of p38 MAP kinase. Matrix Biol 2010, 29:613-620.
71. van den Borne S.W., Diez J., Blankesteijn W.M., Verjans J., Hofstra L., Narula J. Myocardial remodeling after infarction: the role of myofibroblasts. Nat Rev Cardiol 2010, 7:30-37.
72. van Nieuwenhoven F.A., Hemmings K.E., Porter K.E., Turner N.A. Combined effects of interleukin-1α and transforming growth factor-β1 on modulation of human cardiac fibroblast function. Matrix Biol 2013, [in press]. 10.1016/j.matbio.2013.03.008.
73. van Nieuwenhoven F.A., Turner N.A. The role of cardiac fibroblasts in the transition from inflammation to fibrosis following myocardial infarction. Vascul Pharmacol 2013, 58:182-188.
74. Van Tassell B.W., Varma A., Salloum F.N., Das A., Seropian I.M., Toldo S., et al. Interleukin-1 trap attenuates cardiac remodeling after experimental acute myocardial infarction in mice. J Cardiovasc Pharmacol 2010, 55:117-122.
75. Weber A., Wasiliew P., Kracht M. Interleukin-1 (IL-1) pathway. Sci Signal 2010, 3:cm1.
76. Werman A., Werman-Venkert R., White R., Lee J.K., Werman B., Krelin Y., et al. The precursor form of IL-1α is an intracrine proinflammatory activator of transcription. Proc Natl Acad Sci U S A 2004, 101:2434-2439.
77. Westphal E., Li C., Pilowski C., Koch S., Ebelt H., Muller-Werdan U., et al. Endotoxin-activated cultured neonatal rat cardiomyocytes express functional surface-associated interleukin-1α. J Endotoxin Res 2007, 13:25-34.
78. Willems I.E., Havenith M.G., De Mey J.G., Daemen M.J. The alpha-smooth muscle actin-positive cells in healing human myocardial scars. Am J Pathol 1994, 145:868-875.
79. Xiao H., Ji A.M., Li Z.L., Song X.D., Su D., Chen A.H. Interleukin-1β inhibits collagen synthesis and promotes its decomposition in cultured cardiac fibroblasts. Sheng Li Xue Bao 2008, 60:355-361.
80. Xie Z., Singh M., Singh K. Differential regulation of matrix metalloproteinase-2 and -9 expression and activity in adult rat cardiac fibroblasts in response to interleukin-1β. J Biol Chem 2004, 279:39513-39519.
81. Yeh C.C., Li H., Malhotra D., Turcato S., Nicholas S., Tu R., et al. Distinctive ERK and p38 signaling in remote and infarcted myocardium during post-MI remodeling in the mouse. J Cell Biochem 2010, 109:1185-1191.
82. Zeisberg E.M., Kalluri R. Origins of cardiac fibroblasts. Circ Res 2010, 107:1304-1312.
83. Zhang X., Azhar G., Nagano K., Wei J.Y. Differential vulnerability to oxidative stress in rat cardiac myocytes versus fibroblasts. J Am Coll Cardiol 2001, 38:2055-2062.
84. Zhao L., Eghbali-Webb M. Release of pro- and anti-angiogenic factors by human cardiac fibroblasts: effects on DNA synthesis and protection under hypoxia in human endothelial cells. Biochim Biophys Acta 2001, 1538:273-282.
85. Zheng Y., Gardner S.E., Clarke M.C. Cell death, damage-associated molecular patterns, and sterile inflammation in cardiovascular disease. Arterioscler Thromb Vasc Biol 2011, 31:2781-2786.